Varibar Pudding Approved for Use in Oropharyngeal Evaluation

Oropharyngeal impairment can arise from congenital abnormalities or neurologic causes for impaired swallowing
Oropharyngeal impairment can arise from congenital abnormalities or neurologic causes for impaired swallowing

Bracco Diagnostics announced that the Food and Drug Administration (FDA) has approved Varibar Pudding (barium sulfate) oral paste for modified barium swallow (MBS) examinations to evaluate the oral and pharyngeal function and morphology in patients aged ≥6 months.

Oropharyngeal impairment can arise from congenital abnormalities or neurologic causes for impaired swallowing such as cerebrovascular accidents (eg, stroke), tumors, motor neuron disease, demyelinating diseases, connective tissue diseases, metabolic disorders, and infections.  

Related Articles

Prior to the approval of Varibar Pudding, there were no approved barium products for use in MBS exams or validated prescribing information to assure reproducible use and imaging results. Varibar Pudding has a standard 40% w/v ratio of barium sulfate concentration that helps guarantee uniform density, removing the possibility for variable results. It acts as a positive contrast agent for radiographic studies as it is formulated with the minimal coatings required to clearly visualize the swallowing process.

Varibar Pudding is available as a vanilla flavor to help patient compliance. It is supplied as 230mL tubes in 12-count packs. 

For more information call (800) 257-5181 or visit BraccoImaging.com.